ACE2 News and Research

RSS

Study shows how SARS-CoV-2 virus enters cells to cause infection

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection.

24 Jun 2021

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.

24 Jun 2021

Is COVID-19 more severe in pregnancy?

A new study, released as a preprint on the medRxiv* server, indicates that pregnant women are more likely to develop severe disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

24 Jun 2021

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Driven by the mystery of the blood clots reported in both living and deceased COVID-19 patients, researchers from Shoolini University, India, dig deeper into the pathogenesis of COVID-19 and other similar viral diseases, looking for ways in which these clots could be formed.

24 Jun 2021

Green tea catechins might be useful as pan-coronavirus inhibitors

Scientists from the Queen’s University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

Increased severity of COVID-19 in pregnancy

A new preprint on the medRxiv* server provides more evidence that COVID-19 likely causes a more serious phenotype to arise in pregnant women.

23 Jun 2021

SARS-CoV-2 infection and transmission in the North American deer mouse

A recent study conducted in Canada reports that the North American deer mouse can be infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans.

23 Jun 2021

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Researchers have suggested that repeated vaccination against SARS-CoV-2 may enable previously uninfected individuals to cope with viral variants.

23 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

New research published in the journal Viruses suggests recovering from a coronavirus disease 2019 (COVID-19) infection provides immunity against the B.1.1.7 (or UK) variant. The time when the previous infection took place and the variant involved in prior infection influenced cross-neutralization.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

A review published in Phytotherapy Research discussed the natural anti-SARS-CoV-2 products identified based on in silico prediction. The review’s authors also illustrate the impact of many phytochemicals either alone or in combination with traditional treatments and their potential molecular mechanisms involved in SARS-CoV-2 prevention and treatment.

22 Jun 2021

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

A recent study finds that COVID-19 alters the expression of several molecules involved in the homeostasis of blood pressure.

22 Jun 2021

Research identifies SARS-CoV-2 cavities as potential drug targets

New research found the SARS-CoV-2 spike glycoprotein has druggable cavities with the best target being compatible with more than 1 billion compounds.

21 Jun 2021

Can a prior rhinovirus infection protect against COVID-19?

Researchers at the Yale School of Medicine found that rhinovirus accelerates interferon-stimulated genes.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

ACE2 News and Research

Study shows how SARS-CoV-2 virus enters cells to cause infection

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

Is COVID-19 more severe in pregnancy?

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Green tea catechins might be useful as pan-coronavirus inhibitors

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Increased severity of COVID-19 in pregnancy

SARS-CoV-2 infection and transmission in the North American deer mouse

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Researchers review the origins of SARS-CoV-2 and present treatment methods

Engineering nanobodies to fight against the SARS-CoV-2 virus

Researchers screen Chinese herbal medicines and plant compounds for anti-SARS-CoV-2 activity

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

Research identifies SARS-CoV-2 cavities as potential drug targets

Can a prior rhinovirus infection protect against COVID-19?

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News